A Phase Ib/II Study of Ganetespib With Doxorubicin in Advanced Solid Tumors Including Relapsed-Refractory Small Cell Lung Cancer

INTRODUCTION: Small cell lung cancer (SCLC) accounts for 15% of all lung cancers and is characterized by high response rates to cytotoxic chemotherapy and equally high rates of relapse. Many resistance mechanisms have been proposed including resistance to doxorubicin via induction of a heat shock re...

Descripción completa

Detalles Bibliográficos
Autores principales: Subramaniam, Deepa S., Liu, Stephen V., Crawford, Jeanette, Kramer, Jenna, Thompson, Jillian, Wang, Hongkun, Giaccone, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5858550/
https://www.ncbi.nlm.nih.gov/pubmed/29594044
http://dx.doi.org/10.3389/fonc.2018.00064

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5858550/
https://www.ncbi.nlm.nih.gov/pubmed/29594044
http://dx.doi.org/10.3389/fonc.2018.00064

Ejemplares similares